^
    Back
    Association details:
    Biomarker:DAPK1 underexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Aging (Albany NY)
    Title:

    Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma

    Published date:
    11/16/2020
    Excerpt:
    Sunitinib-resistant ccRCC cells show significantly lower DAPK1 mRNA and protein levels than sunitinib-sensitive ccRCC cells.
    DOI:
    https://doi.org/10.18632/aging.103638